Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rhenium-188 resin
- Development stage
- Unknown
- Lead developer
- OncoBeta
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Topical
01
Overview
Rhenium-188 resin (commercially known as Rhenium-SCT) is a therapeutic radiopharmaceutical developed by OncoBeta for the treatment of non-melanoma skin cancer (NMSC), including basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC). It is applied topically as a non-sealed paste or compound onto a protective foil placed over the skin lesion, delivering localized beta radiation (from the beta-emitting radioisotope rhenium-188) up to a depth of 3 mm. This targeted epidermal radionuclide therapy directly damages tumor cell DNA and induces indirect cytotoxicity via reactive oxygen species and bystander effects, while sparing surrounding healthy tissue. It is also being evaluated for other skin conditions such as actinic keratosis, extramammary Paget's disease, and keloid scars.
- Brand names
- Rhenium-SCT
- Other names
- 188Re-resinRe-188 resinRe188 resinRe 188 resinrhenium (188Re) resinrhenium-188 compoundrhenium188 compoundrhenium 188 compoundrhenium-188 pasterhenium188 pasterhenium 188 pasterhenium-188-resinrhenium188-resinrhenium 188-resin
Beyond the preview
Go deeper on rhenium-188 resin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rhenium-188 resin.